Jounce Therapeutics Inc

+0.17 (+3.76%)
Other Pre-Announcement

Jounce Therapeutics Reports First Quarter 2022 Financial Results

Published: 05/05/2022 11:31 GMT
Jounce Therapeutics Inc (JNCE) - Jounce Therapeutics Reports First Quarter 2022 Financial Results.
Q1 Loss per Share $0.72.
Two Combination Cohorts Met Initial Response Criteria for Continued Expansion in Innate Trial of Jtx-8064.
On Track to Present Data on at Least 60 Phase 2 Patients Across Multiple Cohorts in 2h2022.
Target Enrollment Achieved in Select Trial of Vopratelimab in Combination With Pimivalimab; Data Expected in 2h2022.
Jounce Therapeutics- Sees Existing Cash, Cash Equivalents, Investments Sufficient to Enable Funding of Operating Ex, Capex Requirements Through Q3 2023.
Reiterates Its Financial Guidance for 2022.
Gross Cash Burn on Operating Expenses and Capex for Full Year 2022 is Expected to Be Approximately $115.0 Million to $130.0 Million.
Q1 Earnings per Share View $-0.58 -- Refinitiv Ibes Data (analyst estimates).